ArticleToxics2023
Significant Biotransformation of Arsenobetaine into Inorganic Arsenic in Mice.
Article in Toxics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- Tracking Contaminant Trends: PFAS, Metals and Metalloids in Indo-Pacific Bottlenose (Tursiops aduncus) and Common Dolphins (Delphinus delphis) from South Australia.Archives of environmental contamination and toxicology · 2026Article
- Trace Elements in Different Blood Products Used in Neonatal Transfusion: Arsenic and Selenium.International journal of molecular sciences · 2025Article
- Risk assessment of complex organoarsenic species in food.EFSA journal. European Food Safety Authority · 2024Article
- Continuing the Conversation About Arsenic.Integrative medicine (Encinitas, Calif.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Arsenic (As) is extremely toxic to living organisms at high concentrations. Arsenobetaine (AsB), confirmed to be a non-toxic form, is the main contributor to As in the muscle tissue of marine fish. However, few studies have investigated the biotransformation and biodegradation of AsB in mammals. In the current study, C57BL/6J mice were fed four different diets, namely, Yangjiang and Zhanjiang fish diets spiked with marine fish muscle containing AsB, and arsenite (As(III)) and arsenate (As(V)) diets spiked with As(III) and As(V), respectively, to investigate the biotransformation and bioaccumulation of AsB in mouse tissues for 42 d. Different diets exhibited different As species distributions, which contributed to varying levels of As bioaccumulation in different tissues. The intestines accumulated the highest level of As, regardless of form, which played a major part in As absorption and distribution in mice. We observed a significant biotransformation of AsB to As(V) following its diet exposure, and the liver, lungs, and spleen of AsB-treated mice showed higher As accumulation levels than those of As(III)- or As(V)-treated mice. Inorganic As showed relatively high accumulation levels in the lungs and spleen after long-term exposure to AsB. Overall, these findings provided strong evidence that AsB undergoes biotransformation to As(V) in mammals, indicating the potential health risk associated with long-term AsB intake in mammals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.